miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and is the fifth leading cause of cancer deaths in women. Developing adjuvant therapy to circumvent drug resistance represents an important aspect of current initiatives to improve survival in women with advanced EOC. A regulatory molecule that can act on multiple genes associated with a chemoresistant phenotype will be the ideal target for the development of therapeutics to overcome resistance and miRNAs constitute promising tools in this regard. In this review, we discuss the emerging role of miRNAs in regulating EOC phenotype with a focus on prognostic and therapeutic importance of miRNAs and the possibility of miRNA modulation as a tool to improve efficacy of chemotherapy in EOC.
Case Comprehensive Cancer Center, Case Western Reserve University, 2103 Cornell Road, Cleveland, OH 44106, USA.
Anil Belur
AB
Nagaraj
Peronne
P
Joseph
Analisa
A
DiFeo
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D040761:Biomimetic Materials / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D011379:Prognosis
D014408:Biomarkers, Tumor; D035683:MicroRNAs
MRX34; OncomiRs; biomarkers; chemotherapy resistance; epithelial ovarian cancer; miRNA expression profiling; miRNAs; pharmaco-miR; tumor heterogeneity; tumor suppressor miRs